132 related articles for article (PubMed ID: 35718065)
1. Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival.
Santoni M; Monteiro FSM; Massari F; Abahssain H; Aurilio G; Molina-Cerrillo J; Myint ZW; Zabalza IO; Battelli N; Grande E
Crit Rev Oncol Hematol; 2022 Aug; 176():103731. PubMed ID: 35718065
[TBL] [Abstract][Full Text] [Related]
2. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma.
Woodard J; Sassano A; Hay N; Platanias LC
Clin Cancer Res; 2008 Jul; 14(14):4640-9. PubMed ID: 18628479
[TBL] [Abstract][Full Text] [Related]
3. Statin use and the overall survival of renal cell carcinoma: A meta-analysis.
Wu P; Xiang T; Wang J; Lv R; Zhuang Y; Wu G
Clin Invest Med; 2020 Dec; 43(4):E17-23. PubMed ID: 33370521
[TBL] [Abstract][Full Text] [Related]
4. The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy.
Viers BR; Houston Thompson R; Psutka SP; Lohse CM; Cheville JC; Leibovich BC; Tollefson MK; Boorjian SA
Urol Oncol; 2015 Sep; 33(9):388.e11-8. PubMed ID: 25700974
[TBL] [Abstract][Full Text] [Related]
5. Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma.
Hagiwara N; Watanabe M; Iizuka-Ohashi M; Yokota I; Toriyama S; Sukeno M; Tomosugi M; Sowa Y; Hongo F; Mikami K; Soh J; Fujito A; Miyashita H; Morioka Y; Miki T; Ukimura O; Sakai T
Cancer Lett; 2018 Sep; 431():182-189. PubMed ID: 29778569
[TBL] [Abstract][Full Text] [Related]
6. Statins and survival outcomes in patients with metastatic renal cell carcinoma.
McKay RR; Lin X; Albiges L; Fay AP; Kaymakcalan MD; Mickey SS; Ghoroghchian PP; Bhatt RS; Kaffenberger SD; Simantov R; Choueiri TK; Heng DY
Eur J Cancer; 2016 Jan; 52():155-62. PubMed ID: 26687834
[TBL] [Abstract][Full Text] [Related]
7. Impact of statin on renal cell carcinoma patients undergoing nephrectomy. Does it affect cancer progression and improves survival? A Systematic Review and Meta-Analysis.
Adli G; Yogiswara N; Gde Tirta Yoga Yatindra IB; Putra RM; Djatisoesanto W
Arch Ital Urol Androl; 2023 Oct; 95(3):11672. PubMed ID: 37791546
[TBL] [Abstract][Full Text] [Related]
8. YM155 Reverses Statin Resistance in Renal Cancer by Reducing Expression of Survivin.
Nitta T; Koike H; Miyao T; Miyazawa Y; Kato H; Furuya Y; Sekine Y; Suzuki K
Anticancer Res; 2017 Jan; 37(1):75-80. PubMed ID: 28011476
[TBL] [Abstract][Full Text] [Related]
9. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.
Xiong Z; Zang Y; Zhong S; Zou L; Wu Y; Liu S; Fang Z; Shen Z; Ding Q; Chen S
Oncotarget; 2017 May; 8(18):30151-30161. PubMed ID: 28404914
[TBL] [Abstract][Full Text] [Related]
10. Statin use and the risk of renal cell carcinoma: national cohort study.
Chou YC; Lin CH; Wong CS; Chou WY; Chang JY; Sun CA
J Investig Med; 2020 Mar; 68(3):776-781. PubMed ID: 31822508
[TBL] [Abstract][Full Text] [Related]
11. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis.
Horiguchi A; Sumitomo M; Asakuma J; Asano T; Asano T; Hayakawa M
Clin Cancer Res; 2004 Dec; 10(24):8648-55. PubMed ID: 15623649
[TBL] [Abstract][Full Text] [Related]
12. Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts.
Liu W; Choueiri TK; Cho E
Cancer; 2012 Feb; 118(3):797-803. PubMed ID: 21751202
[TBL] [Abstract][Full Text] [Related]
13. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
[TBL] [Abstract][Full Text] [Related]
14. Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation.
Neumann E; Klaiber P; Freitag K; Schwab M; Schaeffeler E; Hennenlotter J; Fend F; Kruck S; Scharpf M; Stenzl A; Bedke J; Rausch S
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1835-1843. PubMed ID: 31006846
[TBL] [Abstract][Full Text] [Related]
15. Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN.
Deng W; Han W; Fan T; Wang X; Cheng Z; Wan B; Chen J
Biomed Pharmacother; 2018 Nov; 107():1505-1513. PubMed ID: 30257368
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting prenylation augments chemotherapy efficacy in renal cell carcinoma through dual inhibition on mitochondrial respiration and glycolysis.
Huang J; Yang X; Peng X; Huang W
Biochem Biophys Res Commun; 2017 Nov; 493(2):921-927. PubMed ID: 28943437
[TBL] [Abstract][Full Text] [Related]
17. Long-term Use of Statins and Risk of Renal Cell Carcinoma: A Population-based Case-Control Study.
Pottegård A; Clark P; Friis S; Hallas J; Lund L
Eur Urol; 2016 May; 69(5):877-82. PubMed ID: 26603781
[TBL] [Abstract][Full Text] [Related]
18. The pro-apoptosis effect of sinomenine in renal carcinoma via inducing autophagy through inactivating PI3K/AKT/mTOR pathway.
Deng F; Ma YX; Liang L; Zhang P; Feng J
Biomed Pharmacother; 2018 Jan; 97():1269-1274. PubMed ID: 29145153
[TBL] [Abstract][Full Text] [Related]
19. The association between statin medication and progression after surgery for localized renal cell carcinoma.
Hamilton RJ; Morilla D; Cabrera F; Leapman M; Chen LY; Bernstein M; Hakimi AA; Reuter VE; Russo P
J Urol; 2014 Apr; 191(4):914-9. PubMed ID: 24291547
[TBL] [Abstract][Full Text] [Related]
20. Statin utilization improves oncologic and survival outcomes in patients with dyslipidemia and surgically treated renal cell carcinoma.
Berquist SW; Lee HJ; Hamilton Z; Bagrodia A; Hassan AE; Beksaç AT; Dufour CA; Wang S; Mehrazin R; Patterson A; Derweesh IH
Minerva Urol Nefrol; 2017 Oct; 69(5):501-508. PubMed ID: 28376607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
